[go: up one dir, main page]

AR133703A1 - DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS FOR ITS PREPARATION AND USE - Google Patents

DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS FOR ITS PREPARATION AND USE

Info

Publication number
AR133703A1
AR133703A1 ARP240102327A ARP240102327A AR133703A1 AR 133703 A1 AR133703 A1 AR 133703A1 AR P240102327 A ARP240102327 A AR P240102327A AR P240102327 A ARP240102327 A AR P240102327A AR 133703 A1 AR133703 A1 AR 133703A1
Authority
AR
Argentina
Prior art keywords
oxoindoline
hydroxypentan
carboxamide
fluorophenyl
fluoro
Prior art date
Application number
ARP240102327A
Other languages
Spanish (es)
Inventor
Sunil Battu
Tian Wei Chou
Iva Darieva Trantcheva
Craig Sather
Allison Duross
Bailey Coker
Tyler Clikeman
Heather Ann Wenzel
Britta Handyside
Suresh Kumar Agarwal
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR133703A1 publication Critical patent/AR133703A1/en

Links

Landscapes

  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona formas sólidas de N-(1-(2-cloro-3-fluorofenil)-1-hidroxipentan-2-il)-7-fluoro-2-oxoindolina-4-carboxamida, composiciones farmacéuticas y formas de dosificación de estas, y métodos para su uso. Las formas sólidas de N-(1-(2-cloro-3-fluorofenil)-1-hidroxipentan-2-il)-7-fluoro-2-oxoindolina-4-carboxamida pueden ser útiles en el tratamiento de enfermedades mediadas por a-1-antitripsina.This description provides solid forms of N-(1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide, pharmaceutical compositions and dosage forms thereof, and methods for their use. Solid forms of N-(1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide may be useful in the treatment of α-1-antitrypsin-mediated diseases.

ARP240102327A 2020-03-01 2024-08-30 DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS FOR ITS PREPARATION AND USE AR133703A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063560597P 2020-03-01 2020-03-01
US202063560598P 2020-03-01 2020-03-01
US202063535864P 2020-08-31 2020-08-31
US202063593495P 2020-10-26 2020-10-26
US202363535854P 2023-08-31 2023-08-31

Publications (1)

Publication Number Publication Date
AR133703A1 true AR133703A1 (en) 2025-10-22

Family

ID=97521936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102327A AR133703A1 (en) 2020-03-01 2024-08-30 DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS FOR ITS PREPARATION AND USE

Country Status (1)

Country Link
AR (1) AR133703A1 (en)

Similar Documents

Publication Publication Date Title
DOP2023000041A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
CY1124432T1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF N-(3,5-DIMETHODIPHENYL)-N'-(1-METHYLATHYL)-N-[3-(1--METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANO- 1,2-DIAMINE
DOP2025000034A (en) INHIBITION OF HUMAN α4β7 INTEGRIN
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
BR112015032736A2 (en) crystalline bromodomain inhibitors
CL2023003518A1 (en) New salts and crystalline forms of n,n-dimethyltryptamine salts
BR112015018087A8 (en) compound, pharmaceutical composition and use
DOP2023000037A (en) PHOSPHOLIPIDS COMPOUNDS AND THEIR USES
CO5640037A2 (en) DERIVATIVES OF QUINAZOLINE FOR THE TREATMENT OF CANCER
CO2023013050A2 (en) Psilocybin compositions, methods of preparing them and methods of using them
CL2024002767A1 (en) Nlrp3 modulators
CO2024005925A2 (en) Small molecules for cancer treatment
BR112023018237A2 (en) PHENALKYLAMINES AND METHODS FOR MANUFACTURE AND USE THEREOF
ECSP21067816A (en) PHARMACEUTICAL FORMULATIONS
MX2022000646A (en) DERIVATIVES OF N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-IL)CARBAMOIL)-4,5,6,7- TETRAHYDROBENZOFURAN-2-SULFONAMIDE AND RELATED COMPOUNDS AS MODULATORS OF NLPR3 FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS).
CO2022014499A2 (en) nlrp3 modulators
CO2023008676A2 (en) Lactam modified polypeptide compounds
MX2024008450A (en) Piperidinyl-methyl-purine deuterium-enriched amines and related compounds and their use in the treatment of diseases and conditions
CL2024003231A1 (en) Heteroaryl derivative compounds and their use in treating pain.
AR044452A1 (en) COMBINATION OF A P2X7 RECEIVER ANTAGONIST AND AN ALFA TUMOR NECROSIS FACTOR INHIBITOR
CL2024001231A1 (en) Crystalline forms of quinazoline derivatives, preparation, composition and use of these
MX2021002444A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS.
AR133703A1 (en) DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS FOR ITS PREPARATION AND USE
MX2020001547A (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dio xolo[4,5-f]indol-7-yl)pyrrole-2,5-dione.
CO2024002715A2 (en) Radiprodil formulations